|
NEWSLETTER N°6 / November 2025
|
|
|
|
|
|
Welcome to the
6th Long COVID Newsletter!
We are pleased to present the 6th edition of our Long COVID EU project newsletter. This issue provides an overview of recent publications, engagement activities, and ongoing communication efforts.
|
|
The Long COVID project is a 4-year research project funded by the EU and coordinated by the Helsinki University Hospital (HUS). Since June 1, 2022, the consortium has been working together to understand the mechanisms of host-virus response underlying the long-term symptoms following SARS-CoV-2 infection.
|
|
|
|
|
|
|
|
Insights from the 3rd webinar - Exploring Biomarkers: Insights into the Long COVID EU Project
|
On 23rd of May 2025, the Long COVID EU Project hosted its 3rd webinar, dedicated to exploring the role of biomarkers in understanding the mechanisms of Long COVID. The event brought together researchers, clinicians, and a diversity of stakeholders to hear three scientific talks highlighting progress in lipidomics, immunoprofiling, and genetics.
|
- Long COVID and Lipids
Dr. Olya Vvedenskaya from Lipotype opened the scientific programme with a talk on lipidomics and its relevance for Long COVID. She introduced lipids as fundamental molecules in the human body, being essential components of cell membranes, energy storage, hormone production, and brain health. Lipid composition, particularly the balance between saturated and unsaturated fats, strongly influences cell membrane flexibility, metabolic regulation, and inflammatory processes. In the context of Long COVID, lipid metabolism appears to be altered in several organs, including the brain, lungs, kidneys, and heart. Early studies indicate disruptions in fatty acid metabolism, mitochondrial function, and chronic inflammation. By analysing the plasma lipidome, researchers aim to identify biomarkers that distinguish recovered patients from those experiencing persistent symptoms. Within the project, Lipotype has analysed over 1,500 plasma samples using mass spectrometry–based lipidomics. The ongoing work seeks to pinpoint specific lipid species associated with energy metabolism impairments and chronic inflammation, potentially enabling the development of diagnostic tests for Long COVID in the future.
- Immunoprofiling of Antibody Immune Response
The second presentation was delivered by Dr. Natalia Pervjakova from Protobios, who shared insights on immune profiling technologies. Protobios has developed a patented method called Mimotope Variation Analysis (MVA), which allows researchers to map the antibody immune response in great detail. By generating synthetic immune repertoires and analysing their interactions with patient antibodies, MVA provides deep insights into how individuals respond to infections and treatments. Dr. Pervjakova explained how this approach can distinguish between responders and non-responders to therapies, support drug development, and identify predictive immune signatures for disease susceptibility. In the case of Long COVID, the team observed strong evidence that infection with SARS-CoV-2 can trigger reactivation of latent viruses such as Epstein-Barr virus (EBV). Elevated EBV markers were detected in a large proportion of Long COVID patients, suggesting that viral reactivation may contribute significantly to persistent symptoms. The research also points to broader patterns of impaired immune control, where other latent viruses such as cytomegalovirus or herpes simplex may prolong Long COVID symptoms. Protobios aims to integrate immunoprofiling data with genetic, metabolic, and microbiome data from project partners, building a comprehensive picture of the disease mechanisms.
- Sick and Tired of Long COVID? Genetics Helping to Understand Disease Mechanisms
The final talk, given by Dr. Vilma Lammi from the University of Helsinki, focused on the genetic underpinnings of Long COVID. She outlined how the international Long COVID Host Genetics Initiative, involving studies from nearly 20 countries, is investigating why some people recover quickly while others develop long-lasting symptoms. Genetic studies have already identified a significant risk locus on chromosome 6, near the FOXP4 gene, which is linked to lung function and immune regulation. Individuals carrying a specific genetic variant in this region face a higher risk of developing Long COVID. Other associations have been found in genes related to immune system regulation, blood groups, and olfactory receptors, offering insights into why symptoms such as fatigue, shortness of breath, or loss of smell persist in certain individuals. These findings not only help uncover the biological pathways involved in Long COVID, but also open the door to new diagnostic tools and drug repurposing opportunities. By combining genomic data with functional and clinical information, researchers of the Long COVID Project aim to identify biomarkers that could guide personalised medicine approaches and inform public health strategies.
|
|
The webinar ended with an interactive Q&A, allowing attendees to engage with experts and enhance their understanding of biomarkers in Long COVID.
|
A warm thank you to all who contributed to advancing this important discussion.
|
Join us for the next webinar in our Webinar series!
|
|
We’re excited to continue our webinar series, offering more opportunities for learning, exchange, and collaboration.
|
Our next webinar is scheduled for 18th of November 2025, and will focus on the effect of SARS-CoV-2 in neurons. We’re thrilled to have our partners from the University of Helsinki and the University of Zurich share their insights on:
|
- SARS-CoV-2 does not infect human neurons efficiently. Lessons learnt from laboratory grown neurons.
- SARS-CoV-2 readily replicates in the brain of susceptible mice. Lessons learnt from a worst case scenario.
|
Following the presentations, there will be an interactive Q&A session, where participants can engage with our expert speakers and ask questions.
|
|
Don’t miss this valuable opportunity to deepen your understanding of Long COVID research.
|
|
Secure your spot today by registering here!
|
|
|
|
|
|
Recent Long COVID project publications
|
|
|
Serum antineuronal antibodies in patients with post-COVID-19 condition - association to intensive care
|
Authors: Tatiana Posharina1, Mikko Varonen1,2, Hanna Jarva5 , Mari Kanerva1,3 , Helena Liira1,2, Sini M Laakso4
|
|
1 Outpatient Clinic for Long-Term Effects of COVID-19, University of Helsinki and Helsinki University Central Hospital, Paciuksenkatu 21, 00270 Helsinki, Finland
|
|
2 Rehabilitation Outpatient Clinic for Persistent Symptoms, Pasila and Meilahti, University of Helsinki and Helsinki University Central Hospital, Finland
|
|
3 Turku University Hospital and University of Turku, Turku, Finland
|
|
4 Translational Immunology Research Program, University of Helsinki and Brain Center, Helsinki University Hospital, Helsinki, Finland
|
5 HUS Diagnostic center, University of Helsinki and Helsinki University Central Hospital, Finland
|
Doi: 10.1016/j.bbi.2025.05.026
|
|
Published on October 2025, Brain, Behavior, and Immunity.
|
|
Introduction
|
Post-COVID-19 condition (PCC) encompasses persistent, often neurological, symptoms emerging ≥3 months after SARS-CoV-2 infection and persist ≥2 months without an alternative diagnosis. Neurological symptoms are common in PCC, and immune-mediated mechanisms have been proposed as potential contributors.
|
|
In this study, serum antineuronal antibodies in patients with PCC were explored, as well as clinical factors associated with seropositivity.
|
|
Methods
|
|
|
|
This prospective single-center cohort study was conducted at the Clinic for Long-Term Effects of COVID-19 at the Helsinki University Hospital from June 2021 to May 2023. Inclusion criteria were PCC diagnosis, age ≥16 years, and PCR- or serology-confirmed prior COVID-19 ≥3 months earlier. All patients underwent a comprehensive clinical interview and examination based on their presenting symptoms. Appropriate diagnostic tests were ordered, such as brain magnetic resonance imaging (MRI), spiroergometry, spirometry and assessments of the autonomic nervous system. Additionally, all patients underwent standardised laboratory investigations (including the serum neuronal autoantibodies screening test) according to protocol to rule out other potential causes of their symptoms. Furthermore, all patients completed structured questionnaires that included screening for possible depression and anxiety.
|
|
|
|
|
A control group of 35 individuals with confirmed prior SARS-CoV-2 infection but without PCC symptoms was also included.
|
|
|
|
Results
Among the 314 PCC patients, 38 (12.1%) were seropositive for antineuronal antibodies. Seven seropositive patients and five seronegative patients underwent CSF analysis; no intrathecal autoantibodies were detected. Demographics (age, sex, time from acute illness to sampling) did not differ between seropositive and seronegative groups. Symptom profiles—fatigue, exertional intolerance, sleep disturbance, dyspnoea, pain, headache, cognitive complaints, and cardiovascular symptoms—were comparable across groups. Brain MRI (performed in 71% of seropositive patients) showed no findings consistent with autoimmune encephalitis; neurological examinations were unremarkable.
|
The most frequent targets among seropositive sera were CASPR-2 (18.4%), neurofascin-186 (13.2%), and glycine receptor (10.5%). Notably, intensive care unit (ICU) admission during the acute infection was the only independent predictor of seropositivity; hospitalisation without ICU care was not associated. Antibody specificity did not map to distinct clinical phenotypes—patients with the same antibody showed heterogeneous symptom constellations.
|
In the matched control group (n=35; prior SARS-COV-2 infection, no PCC), two individuals (5.7%) were seropositive. The seropositivity rate did not differ significantly between PCC and controls (12.1% vs 5.7%). Given that published background rates up to ~5% have been reported in people without autoimmune encephalitis and the testing laboratory estimates 0–2% in healthy controls, the observed difference provides, at most, a trend without statistical support.
|
Neuropsychological testing suggested a trend toward deficits in attention and executive functions among seropositive PCC participants; however, similar impairments have been documented after ICU-treated COVID-19 irrespective of antibody status, limiting causal inference.
|
Conclusion
|
The study observed a low prevalence of serum antineuronal antibodies in PCC patients and a significant association with ICU treatment, pointing toward broad systemic immune activation rather than targeted autoimmunity. The findings do not support antineuronal antibody-mediated mechanisms as a cause of PCC-related neurological symptoms. From a clinical perspective, broad screening for antineuronal antibodies in PCC patients should be approached with caution, and positive results must be carefully interpreted to avoid unnecessary or potentially harmful treatments. It remains, however, unclear whether observed neuropsychological deficits are attributable to autoantibodies or to the effects of critical illness.
|
|
|
|
|
|
Facilitators and barriers for return to work among patients with post-COVID-19 condition: a qualitative interview study
|
Authors: Aleksandra Sulg 1,2, Aki Vuokko 3, Kirsi Kvarnström 1, Mikko Varonen 1, Antti Malmivaara 4, Jari Arokoski 5, Helena Liira 1
|
|
1 Outpatient Clinic for Persistent Symptom Rehabilitation, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
|
|
2 Terveystalo, Occupational Health Clinic, Helsinki, Finland.
|
|
3 Finnish Institute of Occupational Health, Helsinki, Finland.
|
|
4 Finnish Institute for Health and Welfare, University of Helsinki, Orton Orthopedic Hospital, Helsinki, Finland.
|
5 Department of Internal Medicine and Rehabilitation Medicine, Division of Rehabilitation Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.
|
Doi: 10.1080/02813432.2025.2525434
|
|
Published in July 2025, Scandinavian Journal of Primary Health Care
|
|
|
|
Introduction
|
Post-COVID-19 condition (PCC) can negatively impact various aspects of life, including quality of life, mental health, daily functioning, social interactions and work ability. Research indicates that many patients with PCC struggle with work ability and returning to work (RTW). Some studies report prolonged work absences lasting months or even years and many continue to face challenges upon RTW. This qualitative study set out to describe, from patients’ perspectives, what facilitates and hinders return-to-work (RTW) after PCC, so that support can be better tailored across individuals, workplaces, healthcare, and social security systems.
|
|
|
|
Methods
|
Within a larger PCC cohort, the team at the Outpatient Clinic for the Long-Term Effects of COVID-19 at Helsinki University Hospital conducted semi-structured telephone interviews in spring 2023 with 32 working-age patients, of whom 28 were included in the analysis, while four interviews served as pilots. Eligibility focused on patients infected in 2022 (PCR-verified, Omicron variant), aged 18–65, and currently employed or planning RTW. Interviews covered health, daily functioning, work situation, RTW actions, occupational health and workplace arrangements, and rehabilitation experiences. Patients also rated current health, daily functioning (work/social/home), and work ability on 0–10 visual analogue scales; they classified themselves as fully/partially/unable to work. Demographic and clinical information came from clinic surveys and hospital records. Transcripts were analysed using an inductive thematic approach by a multidisciplinary research team; descriptive statistics summarised the structured ratings.
|
|
|
|
Results
|
Participants averaged 46 years; 71% were female and employed across diverse sectors. At interview (mean 14 months post-infection and experiencing symptoms), 54% felt fully able to work, 28% partially able, and 18% unable. Mean self-ratings (0–10) were 6.3 for current health, 6.4 for current work ability, 6.4 for work and social functioning, and 7.2 for home functioning. RTW negotiations occurred in 43% of cases and were helpful for 75% of those who had them.
|
Five theme domains captured facilitators and barriers:
|
(A) Individual-related factors: Facilitators included self-guided rehabilitation (graded walking, cycling, swimming, gentle gym), stress-management (pacing, sleep routines, breathing/mindfulness, yoga, cold-water swimming), positive mindset, patience, and motivation. Barriers were fatigue, cognitive impairments (concentration/word-finding problems), pain, sleep disturbance, palpitations, and overwhelm, alongside worry, catastrophic thoughts, and reduced stress tolerance—often making even small tasks difficult.
|
(B) Work-related factors: Facilitators were flexible arrangements (partial sick leave at 40–60% workload, temporary task modification, adjusted hours/pace), remote-work options, supportive supervisors/colleagues, and meaningful work. Barriers included inflexible workloads, time pressure, limited task control, scepticism about “invisible” symptoms, poor atmosphere, staff shortages, and constant changes—driving mental and cognitive strain and consuming recovery energy.
|
(C) Healthcare-related factors: Facilitators included multidisciplinary occupational health (clear explanations, active listening, realistic planning), regular follow-up, and tripartite RTW meetings (employee–employer–physician). Patients valued the clinic’s psychophysical physiotherapy, peer groups, internet cognitive-behavioural-therapy, and an amygdala–insula retraining program for symptom coping; medications (e.g., beta-blockers, montelukast) sometimes helped specific symptoms. Barriers were insufficient psychological support, limited access, poor coordination, and low PCC knowledge in some services; some found certain interventions cognitively taxing.
|
(D) Social environment factors: Understanding and emotional support from family/friends, peers, and workplace communities fostered safety and confidence; lack of recognition of non-visible symptoms hindered progress.
|
(E) Social insurance factors: Partial sick-leave arranged by the Social Insurance Institution benefits enabled graded RTW; conversely, not meeting benefit criteria created stress, perceived unfairness, and administrative burden.
|
Conclusion
|
PCC-related work disability is multifactorial, shaped by interacting individual, workplace, healthcare, social, and insurance determinants. Effective support requires a holistic, collaborative approach: patient-centred education and coaching (pacing, graded activity, stress-management), psychologically safe and flexible workplaces (task/tempo/remote adaptations, supportive leadership), accessible multidisciplinary care (clear explanations, follow-up, RTW negotiations, targeted rehab options), and enabling social security mechanisms (e.g., partial benefits for graded RTW). The study’s strengths include in-depth qualitative insights from a largely non-hospitalised, working-age PCC cohort; limitations include cross-sectional design, female over-representation, and potential selection and recall biases. Overall, aligning patients, employers, healthcare, and insurers around graduated, person-specific RTW plans appears central to sustaining work participation in PCC.
|
|
|
|
|
|
Basel Long COVID Cohort Study (BALCoS): protocol of a prospective cohort study
|
Authors: Stefan Rohner 1,2, Rebekka Schnepper 2,3, Gunther Meinlschmidt 1,2,4,5, Rainer Schaefert 1,2, Michael Mayr 1,6, Katrin Bopp 1,6, Andrea Meienberg 1,6
|
|
1 Faculty of Medicine, University of Basel, Basel, Switzerland.
|
|
2 Department of Psychosomatic Medicine, University Hospital Basel, Basel, Switzerland.
|
|
3 Digital and Blended Psychosomatics and Psychotherapy, University of Basel, Basel, Switzerland.
|
|
4 Department of Digital and Blended Psychosomatics and Psychotherapy, University Hospital Basel, Basel, Switzerland.
|
|
5 Department of Clinical Psychology and Psychotherapy - Methods and Approaches, University of Trier, Trier, Germany.
|
|
6 Medical Outpatient Clinic, University Hospital Basel, Basel, Switzerland.
|
7 Faculty of Medicine, University of Basel, Basel, Switzerland andrea.meienberg@usb.ch
|
Doi: 10.1136/bmjopen-2024-093981
|
|
Published on 10th of July 2025, BMJ Open
|
|
Introduction
|
Post-COVID-19 condition (PCC) encompasses heterogeneous, often disabling symptoms that persist for ≥2 months following a SARS-CoV-2 infection and cannot be explained by another diagnosis. Although several risk factors have been identified, such as virus variant, female sex, hypertension, obesity, smoking and pre-existing comorbidities, the underlying mechanisms of PCC remain poorly understood. While biomedical mechanisms remain a primary focus, PCC is increasingly recognised as a complex, multifactorial condition. Psychological, social and behavioural factors have also been shown to influence both symptom severity and illness persistence. Due to the limited understanding of PCC pathogenesis, current treatment strategies primarily aim at symptom management. This lack of clarity may contribute to the psychological burden experienced by affected individuals, including frustration, helplessness, uncertainty about disease course and reduced sense of control.
|
|
|
|
Study Objectives
The protocol outlines the Basel Long COVID Cohort Study (BALCoS), which aims to investigate and improve the understanding of PCC, its clinical manifestations, symptom trajectories and underlying multifactorial mechanisms. BALCoS is a registry-based, single-centre, prospective observational cohort at the University Hospital Basel Medical Outpatient Clinic. The study is prospective and observational in design and captures data at baseline and 3 months, 6 months and 12 months. Core objectives include:
|
- Characterisation of clinical presentations and symptom patterns of individuals with PCC
- Description of demographic, clinical and laboratory profiles of affected individuals
- Identification of potential risk factors for the development and persistence of PCC
- Longitudinal evaluation of symptom trajectories and functional outcomes over time
- Assessment of the impact of PCC on health-related quality of life, psychosocial well-being, functional status and work ability
- Analysis of prior treatment experiences, healthcare utilisation and potential unmet care needs in individuals with PCC
|
Methods and Analysis
Recruitment began February 2023 (first enrolment April 2023) and is planned to continue beyond May 2026. Study included German-speaking adults (≥18 years) with prior SARS-CoV-2 infection and persistent symptoms consistent with the WHO definition of PCC. In 2024, inclusion was broadened to reflect reduced acute-phase testing nationally, allowing probable infections by history. Exclusions are inability to understand procedures or refusal of consent. Envisaged target sample size is 120.
|
Study assessments are scheduled at four timepoints: at baseline (BL) and at 3 months (T1), 6 months (T2) and 12 months (T3) after baseline. All participants complete psychometric questionnaires at every time point. In-person participants additionally undergo neurocognitive testing and physical performance measures at BL and T3; blood sampling occurs at BL only. Remote participation is offered (questionnaires + ecological momentary assessments only).
|
- Psychometric questionnaires to assess: functional capacity, quality of life, somatic symptom severity, somatic distress, depression, anxiety, resilience, insomnia, fatigue, stress, symptom intensity, functional impairment, and work capacity.
- Neurocognition: Central Nervous System Vital Signs (computerised neurocognitive test battery comprising 7 neuropsychological tests)
- Physical performance test to assess: functional exercise capacity, handgrip strength, muscular endurance
- Ecological Momentary Assessment (EMA): 8 ultra-brief items delivered daily for 10 consecutive days after BL, T1, T2, T3 to capture fluctuations in mood, stress, social support, daily activities, mindfulness, and self-compassion
- Biospecimens: standard blood testing (blood count, inflammatory markers and liver and kidney function), genomic and human leucocyte antigen typing (plasma), COVID-19 antibody profiling (serum), lipidomic profiling (serum), characterisation of autoantibody epitopes (serum), coagulation markers (citrated plasma).
Conclusion
|
BALCoS is an ongoing study and will provide multi-domain, longitudinal data on adults with PCC, integrating routine clinical information, rich psychometrics, neurocognitive and physical function tests, real-time EMA, and targeted biomarker panels. By characterising trajectories and potential risk factors, and by situating biomedical findings alongside psychosocial determinants, the study aims to refine how PCC severity is measured, illuminate mechanisms, and inform integrated, patient-centred care and rehabilitation strategies.
|
|
|
|
|
|
|
|
6th Consortium Meeting in Helsinki
|
|
|
|
The project convened its 6th consortium meeting in Helsinki on 18th – 19th of June, gathering all partners to provide updates, review progress, and establish priorities for the coming year. Notably, two patient representatives from the COFFI collaborative participated, contributing valuable insights and guidance on incorporating the patient perspective into our research efforts.
|
|
Day one started with introductory remarks from the project coordinator (HUS) and our host (Spinverse), followed by comprehensive work package presentations detailing recent scientific progress. The agenda also included discussions to establish the roadmap for the final year of the project.
|
|
|
|
|
On the second day, participants engaged in an interactive session with group activities focused on planning the development of the final publication, which will offer an integrated summary of the project's outcomes. Additionally, attention was given to non-scientific work packages, including project management, dissemination, communication, and exploitation. A notable highlight was the insightful feedback provided by patient representatives from the COFFI collaborative, who contributed their perspectives throughout the meeting.
|
|
Long COVID Project: Successful 2nd Review Meeting Highlights Major Progress
|
|
|
|
On the 1st of October 2025, the Long COVID consortium gathered for its 2nd Review Meeting, hosted by Spinverse and led by Project Coordinator Helena Liira. The meeting brought together the European Commission Project Officer, external reviewers, and all Work Package leaders to showcase the project’s impressive progress during the second reporting period (Dec 2023 – May 2025).
|
|
From the opening remarks, it was clear that the project has entered a decisive and productive phase. With 14 scientific articles published, GDPR-compliant data management, and strong collaboration across clinical, mechanistic, and AI research, the consortium has laid a robust foundation for the project’s final phase.
|
|
Throughout the whole day, the WP leaders presented their key achievements, WP status and next steps, followed by intensive discussions and Q&As with our project officer and reviewers.
|
|
The project officer and reviewers commended the consortium’s scientific excellence, collaboration, and commitment. Further, they provided guidance and advice for the successful completion of the Long COVID project.
|
|
|
|
|
Upcoming Milestones and Events
|
|
|
Our 4th Webinar - An update on the effect of SARS-CoV-2 in neurons: Lessons learnt from laboratory experiments
|
The next webinar will take place on the 18th of November and is dedicated to explore the gain insights into the project’s mechanistic research. Secure your spot and register here.
|
|
|
|
|
|
Peer-reviewed scientific publications
|
|
|
- Rohner, Stefan; et al. Basel Long COVID Cohort Study (BALCoS): protocol of a prospective cohort study. BMJ Open. 2025. doi: 10.1136/bmjopen-2024-093981
- Sulg, Aleksandra; et al. Facilitators and barriers for return to work among patients with post-COVID-19 condition: a qualitative interview study. Scand J Prim Health Care. 2025. doi: 10.1080/02813432.2025.2525434
- Posharina, Tatiana; et al. Serum antineuronal antibodies in patients with post-COVID-19 condition – association to intensive care. Brain Behav Immun. 2025. doi: 10.1016/j.bbi.2025.05.026
- Lammi, Vilma; et al. Genome-wide association study of long COVID. Nat Genet. 2025. doi: 10.1038/s41588-025-02100-w
- Karisola, Piia; et al. Patients with post-COVID-19 condition show minor blood transcriptomic changes, with altered erythrocyte gene expression in a male subgroup. Frontiers in immunology. 2025. doi:10.3389/fimmu.2025.1500997
- Vangelova-Korpinen, Velina; et al. Effectiveness of mindfulness-based online therapy or internet-delivered cognitive behavioral therapy compared with treatment as usual among patients with persistent somatic symptoms: Protocol for a randomized controlled trial. PloS one. 2025. doi:10.1371/journal.pone.0316169
- Ojha, Ravi; et al. Dynamin independent endocytosis is an alternative cell entry mechanism for multiple animal viruses. PLoS pathogens. 2024. doi:10.1371/journal.ppat.1012690
- Stålnacke, S.; et al. Functioning of post-COVID-19 patients: a cross-sectional study at the outpatient clinic for long-term effects. Scand J Prim Health Care. 2024. doi: 10.1080/02813432.2024.2410986
- Tatham, L.; et al. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. Microbiol Spectr. 2024. doi: 10.1128/spectrum.03916-23
- Liira, H.; et al. Prognosis of patients with post-Covid-19 condition: Prospective cohort cluster analysis at one year. J Psychosom Res. 2024. doi: 10.1016/j.jpsychores.2024.111808
- Virrantaus, H.; et al. Prognosis of patients with long COVID symptoms: a protocol for a longitudinal cohort study at a primary care referred outpatient clinic in Helsinki, Finland. BMJ Open. 2023. doi: 10.1136/bmjopen-2023-072935
- De Neck, S.; et al. The Stereotypic Response of the Pulmonary Vasculature to Respiratory Viral Infections: Findings in Mouse Models of SARS-CoV-2, Influenza A and Gammaherpesvirus Infections. Viruses. 2023. doi: 10.3390/v15081637
- Kettunen, P.; et al. SARS-CoV-2 Infection of Human Neurons Is TMPRSS2 Independent, Requires Endosomal Cell Entry, and Can Be Blocked by Inhibitors of Host Phosphoinositol-5 Kinase. Journal of Virology. 2023. doi: 10.1128/jvi.00144-23
|
These publications are also available in the Long COVID Community on Zenodo, a multi-disciplinary open repository maintained by CERN. Furthermore, they can be found on the Long COVID website as well.
|
|
|
|
|
|
|
Project Coordinator
Helena Liira
Helsinki University Hospital
Helsinki, Finland
helena.liira@hus.fi
|
|
Mari Kanerva (Clinical Studies)
|
Helsinki University Hospital
Helsinki, Finland
|
|
Giuseppe Balistreri (Mechanistic Studies)
|
|
|
|
Project Coordinator-Support
Riikka Paasikivi
|
Communication & Dissemination Leader
Lena Schleicher
|
|
lena.schleicher@steinbeis-europa.de
|
|
|
|
|
|
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor HaDEA can be held responsible for them. This project has received funding from the European Union's Horizon Europe reserach and innovation programme under grand agreement No 101057553. This work was supported by the Swiss State for Education, Research and Innovation (SERI) under contract number 22.00094.
|
|
|
|
|
|
|
|
|
